Rheumatology Advance Access originally published online on July 19, 2005
Rheumatology 2005 44(11):1407-1413; doi:10.1093/rheumatology/kei029
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatologists' judgements about the efficacy of anti-TNF therapy in two neighbouring regions
Department of Epidemiology and Public Health, 1 Department of Psychology and 2 Department of Rheumatology, Queen's University of Belfast, Belfast, UK and 3 St Vincent's University Hospital, Dublin, Ireland.
Correspondence to: A. Bell, Arthritis Research Group, QUB Musculoskeletal Education and Research Unit, Musgrave Park Hospital, Belfast BT9 7JB, UK. E-mail: a.bell{at}qub.ac.uk
Objectives. The requirement in Northern Ireland to prescribe biological agents according to National Institute for Clinical Excellence/British Society for Rheumatology (NICE/BSR) guidelines and within a fixed budget has created a waiting list for treatment that has no parallel in the Republic of Ireland. The study investigated the bearing this situation may have had on consultants’ judgements in the respective areas.
Methods. Seventy-eight case vignettes created from the data on real patients with RA treated with biologicals in the north and south of Ireland were appraised by nine southern and eight northern consultants, who judged the clinical benefit and significance of the patients’ condition after a trial of therapy. Quantitative (clinical judgement analysis) and qualitative (focus groups) techniques were used.
Results. Northern consultants perceived a slightly greater degree of clinical benefit after a trial of therapy than southern consultants. Judgement models of northern and southern consultants were broadly comparable. The latter tended to be more uniform in their judgements than the southern group. Focus group discussions with consultants largely validated the findings of the quantitative analysis but revealed how clinical judgement analysis might be misled by gaming strategies.
Conclusions. Despite the absence of overt rationing in the south of Ireland, as far as the judgement of therapeutic benefit from biologicals was concerned, the clinical judgement policies of practitioners were very similar to those in the north. The adoption of NICE/BSR guidelines in the north may have improved the uniformity of clinical practice in Northern Ireland.
KEY WORDS: Anti-TNF-
, Infliximab, Prescribing, Clinical judgement analysis, Ireland, Budget, Waiting list
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. J. Kay, I. D. Griffiths, and for the BSR Biologics Register Management committe UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register Rheumatology, November 1, 2006; 45(11): 1376 - 1379. [Abstract] [Full Text] [PDF]
|
|